

# Molecular imaging study reveals improved detection of early recurrent prostate cancer

September 17 2015

---

A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of *The Journal of Nuclear Medicine*. In the study, the imaging agent—Ga-68 prostate-specific membrane antigen (Ga-68 PSMA)—used with positron emission tomography and computed tomography (PET/CT), changed management in 44% more cases than another widely used agent.

"This is the first prospective comparative trial evaluating detection rates and management impact of the more widely available radiopharmaceutical F-18 fluoromethylcholine (FMC) and the recently developed Ga-68 PSMA PET tracer agent in men with [prostate cancer](#)," said Joshua James Morigi, MD, lead author of the study. "We specifically addressed men with prostate cancer and low PSA levels, at which current imaging techniques struggle in detecting disease."

The researchers, of St. Vincent's Hospital, Sydney, Australia, evaluated 39 prostate cancer patients who had rising PSA following first-round treatment and were eligible for further targeted therapy. Patients on systemic treatment were excluded. Ga-68 PSMA PET/CT, F-18 FMC PET/CT and diagnostic CT were undertaken in all patients sequentially between January and April 2015 and assessed by masked, experienced [nuclear medicine](#) physicians. Researchers then documented scan results and management impact changes, together with histological follow-up, if feasible. Of the patients enrolled, 89 percent had only their prostate gland removed, while the other 11 percent were post-radiation treatment.

"Our main finding is that even at extremely low PSA levels (

Citation: Molecular imaging study reveals improved detection of early recurrent prostate cancer (2015, September 17) retrieved 20 March 2024 from <https://medicalxpress.com/news/2015-09-molecular-imaging-reveals-early-recurrent.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--